← All trials
NCT05774899
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2023
- Primary completion
- Jun 1, 2024
- Completion date
- Jun 1, 2026
- First posted
- Mar 20, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 34
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Cellestia Biotech AGCollaborator
- Adenoid Cystic Carcinoma Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.